CORT vs MDGL
CORT: Corcept Therapeutics is a commercial-stage biotechnology company pioneering cortisol modulation therapies to treat severe endocrine, oncologic, and metabolic conditions. MDGL: Madrigal Pharmaceuticals is a biopharmaceutical company commercializing Rezdiffra, the first and only FDA-approved therapy for adults with metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver fibrosis.
Side-by-side fundamentals
| Metric | CORT | MDGL | Edge |
|---|---|---|---|
| Price as of 2026-07-27 close | $91.12 | $551.25 | |
| Market cap as of 2026-08-03 | $9.8B | $12.7B | |
| P/E as of 2026-08-03 | 261.41 | n/a | |
| PEG as of 2026-08-03 | n/a | -134.35 | |
| Net margin as of 2026-08-03 | +6.2% | -27.3% | CORT higher |
| Gross margin as of 2026-08-03 | +98.3% | +93.1% | CORT higher |
| Operating margin as of 2026-08-03 | -1.1% | -27.9% | CORT higher |
| ROE as of 2026-08-03 | +7.4% | -50.1% | CORT higher |
| ROA as of 2026-08-03 | +5.8% | -25.4% | CORT higher |
| Debt / equity as of 2026-08-03 | 0.00 | 0.63 | CORT lower |
| Revenue growth (YoY) as of 2026-08-03 | +12.2% | +256.8% | MDGL higher |
| Revenue CAGR (3y) SEC XBRL | +23.7% | n/a | |
| Dividend streak (yrs) SEC XBRL | 0 | n/a | |
| Beta as of 2026-08-03 | 0.47 | -1.05 | |
| 1-year return as of 2026-07-27 close | +33.4% | +84.7% | MDGL higher |
Fundamentals: market data, as of 2026-08-03. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-27.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.